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Abstract. Data on Myelodysplastic Syndromes (MDS) are difficult to collect by cancer registries 
because of the lack of reporting and the use of different classifications of the disease. In the Lazio 
Region, data from patients with a confirmed diagnosis of MDS, treated by a hematology center, 
have been collected since 2002 by the Gruppo Romano-Laziale Mielodisplasie (GROM-L) 
registry, the second MDS registry existing in Italy.  
This study aimed at evaluating MDS medical miscoding during hospitalizations, and patients’ 
survival. For these purposes, we selected 644 MDS patients enrolled in the GROM-L registry. 
This cohort was linked with two regional health information systems: the Hospital Information 
System (HIS) and the Mortality Information System (MIS) in the 2002-2012 period.  
Of the 442 patients who were hospitalized at least once during the study period, 92% had up to 
12 hospitalizations. 28.5% of patients had no hospitalization episodes scored like MDS, code 
238.7 of the International Classification of Disease, Ninth Revision, Clinical Modification  (ICD-
9-CM). The rate of death during a median follow-up of 46 months (range 0.9-130) was 45.5%. 
Acute myeloid leukemia (AML) was the first cause of mortality, interestingly a relevant portion 
of deaths is due to cerebro-cardiovascular events and second tumors.  
This study highlights that MDS diagnosis and treatment, which require considerable healthcare 
resources, tend to be under-documented in the HIS archive. Thus we need to improve the HIS to 
better identify information on MDS hospitalizations and outcome. Moreover, we underline the 
importance of comorbidity in MDS patients’ survival. 
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Introduction. Myelodysplastic syndromes (MDS) 
are characterized by hematopoietic impairment 
associated with peripheral blood (PB) cytopenias, 
leading to serious morbidity, and an increased risk 
of leukemic transformation.1 
In the general population, MDS occurs in 3-5 
per 100,000 people/year. However, in individuals 
aged over 70 years, the incidence constantly 
increases up to 40-60 /100,000.2,3 Survival of 
MDS patients is poor,4 with 2-4 years reported 
median overall survival (OS).1,5,6 Factors known to 
impact survival include age, the number of blasts, 
cytogenetic profile, cytopenias, transfusion 
requirements and disease type, according to 2008 
WHO classification.7 Some of these parameters 
have been used to develop MDS prognostic 
indexes: the International Prognostic Scoring 
System (IPSS),8 the Revised International 
Prognostic Scoring System (R-IPSS)9 and the 
WHO-adapted Prognostic Scoring System 
(WPSS).10 The introduction of new treatments in 
the last decade, including hypomethylating and 
immunomodulating agents, improved supportive 
care measures and the more frequent use of 
allogeneic stem cell transplantation (HSCT) are 
changing the natural history of these diseases.11 
Results on MDS from population-based studies 
are rare, and these data are under-reported by 
cancer registries. Underreporting is likely a result 
of inadequate infrastructure of reporting to cancer 
registries or by under diagnosis of MDS 
(i.e. no bone marrow examination performed to 
confirm the MDS diagnosis).  
The reasons why an extensive epidemiological 
analysis has not been conducted are: 
i) the use of the code International Classification 
of Disease, Ninth Revision, Clinical 
Modification (ICD-9-CM) does not specify 
MDS subtypes,12 and a complete international 
classification of diseases for oncology ICD-O-3 
is not usually adopted in Italian medical claim 
databases; 
ii) the inaccuracy of case reporting because 
diagnosis and management are performed by 
different medical service. 
In the last decades, in several countries, many 
registries have been created as the “Surveillance 
and epidemiological and End Results” (SEER) 
from the National cancer Institute,5 the 
“Dusseldorf registry” started in 1986,6 the 
“Netherlands Cancer Registry”, established in 
19892,13 or the “Victorian Cancer Registry”,14 
which provided a basis for epidemiological and 
clinical studies in MDS. 
The incidence of MDS in Italy is not well 
documented because large population-based 
studies are scarce, since oofficial statistics on 
morbidity and mortality is not available on a 
national basis, but derives from some regional 
cancer surveys and hospital-based registries. 
The only registry active in Italy was the 
Piedmont one15 created in 1999, which started as a 
regional database, and has been recently expanded 
to other regions, in the FISM (Federazione Italiana 
Sindromi Mielodisplastiche), but does not include 
the whole Italian territory. 
In the last decades, information from large 
administrative datasets, like hospital or drug 
registries, has been widely used to describe  the 
epidemiological impact of chronic diseases 
through standardized methodologies.16-20 In the 
case of MDS epidemiological figures from 
population-based studies using linked health 
information systems are lacking13 and no study 
exists in Italy to test the quality of claims data in 
this field.   
Based on the experience of international 
epidemiological surveillance, the Gruppo 
Romano-Laziale Mielodisplasie (GROM-L) 
gathered in 2009 to encourage the cooperation 
between the hematological departments in the 
area, to promote the harmonization of clinical and 
diagnostic pathways in MDS. 
It has been built a registry and patients with a 
confirmed diagnosis of MDS are enlisted in the 
GROM-L registry by a hematologic center of the 
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Lazio Region, and the database  is regularly 
updated. 
The study reported here had two main aims: 
1) to evaluate MDS-miscoding in medical claims, 
through the analysis of the concordance 
between the diagnosis of the MDS patients 
enrolled in the GROM-L registry, considered as 
gold-standard, and the diagnosis reported by the 
physician in-charge in the claims recorded 
during the hospitalization episodes in any 
regional hospital, following the MDS 
diagnosis; 
2) to conduct an 11-year mortality follow-up of 
the MDS cohort enrolled in the registry using 
data from the Lazio region mortality registry.  
 
Patients and Methods.  
Data sources. 
a) Clinical dataset: the GROM-L registry 
Our study enrolled patients diagnosed with 
MDS in 12 Hematology Centers in the Lazio 
Region, between 2002 and 2010. Individual data 
were collected in a homogeneous electronic 
platform. About 40% of patients were enrolled 
because of hematologic counseling in a ward 
different from 'hematology,'  20% accessed 
through the emergency room and 40% due to an 
outpatient visit required by their physician. After 
diagnosis, 45% MDS patients were monitored 
through the outpatient clinic, while the remaining 
patients were followed in day-hospital since they 
received transfusions or other treatments. In 
addition, some outpatients needed to access the 
emergency room for severe anemia and were 
admitted to internal medicine wards. The 
information on MDS type according to  2008 
WHO classification was available for each patient. 
b) Healthcare Information Systems 
The following Lazio region healthcare 
databases were used: 
- The Hospital Information System (HIS) 
database for every hospitalization in any hospital 
of region Lazio, containing information on 
patients’ personal data, diagnose of discharge, and 
the procedure performed, encoded according to the 
ICD-9-CM.  
- The regional Mortality Information System 
(MIS) database, including information on 
demographic characteristics, as well as date, place, 
and cause of death (codified by ICD-9-CM codes). 
Data available in the regional Healthcare 
Information Systems are routinely collected for 
administrative purposes. The Department of 
Epidemiology of the Lazio Regional Health 
Service is authorized to manage these databases 
within the rules of the National Privacy Policy. 
Linkage among different information systems is 
possible using an Anonymous Unique Patient 
Code (AUPC) for every citizen enrolled in the 
regional healthcare service.  
Standardized procedures of deterministic record 
linkage are applied to connect the archives, to 
build the clinical history of patients for the 
evaluation of epidemiological studies.1-5 The high 
quality of individual data is the basic requirement 
for epidemiological studies, based on the 
Healthcare Information Systems. 
 
Statistical analysis. A retrospective cohort study 
was conducted. Only patients with a valid AUPC 
were linked to the Healthcare Information 
Systems. 
About the first aim of the study (to evaluate 
MDS-miscoding in medical claims), the HIS for 
the years 2002-2012 was linked to the MDS 
cohort. The ICD-9-CM code used to identify MDS 
is 238.7 (neoplasm of uncertain behavior of other 
lymphatic and hematopoietic tissues). Only 
patients who had at least 1 hospitalization between 
the date of MDS diagnosis by the Hematology 
Center and the end of 2012 were considered. We 
calculated the proportion of patients where the 
238.7 ICD-9-CM code or sub-classification, were 
reported at least once in any principal or secondary 
diagnosis. In patients who had a concordant MDS 
diagnosis, specific ICD-9-CM code recorded for 
MDS in HIS claims were explored. Specific ICD-
9-CM code registered in the principal diagnosis in 
HIS claims were examined for patients who did 
not have a concordant MDS diagnosis. 
About the second aim of the study (to conduct a 
mortality follow-up), the MIS for the years 2002-
2012 was linked to the MDS cohort. Mortality 
follow-up started on the day of the MDS diagnosis 
until 31 December 2012, or the date of death if it 
occurred before. Thus, potentially, each patient 
had a minimum of 2 years and a maximum of 11 
years observation time. The main causes of death 
were examined.  
Time to death was examined using the Kaplan-
Meier curve, stratified by MDS subtype, according 
to 2008 WHO classification. These curves show 
the cumulative probability of surviving during a 
given follow-up time (expressed in months). End
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  Mean age at 
MDS diagnosis 
% women 
  WHO 2008 classification 
    RARS 5q- MDS-U RA RAEB I RAEB II RCMD 
1 32   71.63 59.38   2 3 1 10 7 4 5 
2 67   73.40 62.69   1 8 0 35 5 1 17 
3 27   71.56 29.63   3 0 0 9 3 7 5 
4 104   68.96 34.62   3 1 0 17 21 13 49 
5 125   68.38 44.8   18 5 13 27 18 28 16 
6 31   71.00 45.16   0 0 6 19 1 5 0 
7 37   65.95 56.76   0 1 0 21 5 4 6 
8 43   59.91 32.56   1 3 0 14 5 9 11 
9 82   66.37 46.34   0 2 7 40 15 5 13 
10 48   78.46 45.83   3 2 0 23 9 3 8 
11 38   76.08 47.37   1 1 1 21 5 0 9 
12 10   73.00 50.00   0 1 0 4 0 0 5 
TOTAL 644   69.73 45.50   32 27 28 240 94 79 144 
RA = Refractory anemia; RARS = Refractory anemia with ring sideroblasts; RCMD = Refractory cytopenia with multilineage dysplasia; 
RAEB I = Refractory anemia with excess blasts type I; RAEB II = Refractory anemia with excess blasts type II; MDS-U = MDS 
unclassifiable; 5q- = MDS with isolated del(5q). Hematology centers: (1) Az. Osp. San Giovanni-Addolorata, Rome; (2) Sant'Andrea 
"Sapienza" University, Rome: (3) Az. Osp. San Camillo-Forlanini, Rome; (4) “Sapienza” University, Rome; (5) Università Cattolica del 
Sacro Cuore, Rome; (6) Campus Biomedico University, Rome; (7) Regina Elena National Cancer Institute, Rome; (8) Az. Osp. 
Sant’Eugenio, Rome; (9) Tor Vergata University, Rome; (10) Az. Osp. Sandro Pertini, Rome; (11) Ospedale Nuovo Regina Margherita, 
Rome; (12) Az. Osp. Belcolle, Viterbo. 
 
of the study period (31 December 2012) was 
considered a reason for censoring. Censored 
patients do not contribute to the denominator for 
the succeeding proportion of deaths. The Log-
Rank test was used to compare the full curves of 
each group to evaluate if the seven survival curves 
are statistically significantly different. 
Finally, we analyzed the proportion of patients 
alive stratified by year of diagnosis at one year 
follow up and at five years follow up, therefore for 
the second aim we restricted our analysis to 
patients diagnosed from 2002 to 2007. The Log-
Rank test was performed. 
 
Results. 
Patients’ characteristics. We enrolled 644 patients 
with MDS, diagnosed at 12 Hematology Centers 
of the Lazio Region during the period 2002-2010. 
Table 1 reports patient characteristics according to 
the Hematology Center where the diagnosis was 
made. Mean patients’ age was 69.7 years, and 
45.5% were female. According to the 2008 WHO 
classification, there were 5% RARS, 4.2% 5q- 
syndromes, 4.3% MDS-U, 37.3% RA, 14.6% 
RAEB I, 12.2%  RAEB II and 22.4% RCMD. 
 
MDS miscoding in HIS medical claims. The 
analysis of MDS miscoding in HIS medical claims 
and the Mortality follow-up was limited to 556 
patients with a valid AUPC. 
The data of patients with a correct AUPC 
enrolled by the GROM-L registry per year had to 
be linked with administrative databases. Patients 
who were hospitalized at least once during the 
period 2002-2012 are reported in Table 2. Of the 
442 patients, 92% had a maximum of 12 
hospitalizations for any cause.  
According to the cause of hospitalization 
reported in the principal and secondary diagnoses, 
the 442 patients have been divided into 2 groups: 
 
Table 2. Frequency of patients who were enrolled by the GROM-L 
registry, with a correct anonymous patient code, who had at least 1 
hospitalization episode during the period 2002-2012. (Numbers 









with a valid 
anonymous 
ID 





2002 29 23 22 
2003 39 31 23 
2004 44 35 31 
2005 65 58 49 
2006 67 60 40 
2007 99 86 66 
2008 106 95 80 
2009 115 96 76 
2010 80 72 55 
TOTAL 644 556 442 
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Table 3. Distribution of the sub-diagnostic codes for 238.7 in 180 patients during various hospital admissions. 
Myelodysplastic Syndrome Diagnosis ICD9-CM code 
Patients who had the same ICD9-CM code in all 
hospitalizations during the study period 
N % 
Essential thrombocythemia 238.71 1 0.56 
Low grade myelodysplastic syndrome lesions 238.72 27 15.00 
High grade myelodysplastic syndrome lesions 238.73 18 10.00 
Myelodysplastic syndrome with 5q deletion 238.74 3 1.67 
Myelodysplastic syndrome, unspecified 238.75 40 22.22 
Myelofibrosis with myeloid metaplasia 238.76 0 0.00 
Other lymphatic and hematopoietic tissues 238.79 3 1.67 
Other lymphatic and hematopoietic tissues 238.7 88 48.89 
  Total 180 100 
 
1) 316 patients (71.5%) who had at least 1 
hospitalization with the 238.7 ICD-9-CM code 
in any principal or secondary diagnosis. 
2) 126 patients (28.5%), who had no 
hospitalization with the 238.7 ICD-9-CM code 
in any primary or secondary diagnosis.  
Patients in group 1 were hospitalized 1107 
times during the study period. Of the 316 patients, 
180 had the same diagnosis code 238.7 for all 
hospital admissions. Table 3 shows the 
distribution of code 238.7 for these 180 patients.   
Half of the cases had the diagnosis “MDS 
unspecified” (ICD-9 code 238.75). The remaining 
136 patients had mixed diagnosis within the class 
238.7 for the various hospital admission. 
Of the 126 patients in group 2, 66 patients had 
at least one hospitalization with a primary 
hematologic diagnosis (ICD-9-CM codes 280-289:  
 
Table 4. Distribution of the principal diagnostic codes for the 203 hospitalization in 60 patients who had no hospitalization episodes with the 
ICD9-CM code 238.7 or  another hematologic code. 
PRINCIPAL DIAGNOSES ICD9-CM CODES N % 
MALIGNANT NEOPLASM OF LYMPHATIC AND 
HEMATOPOIETIC TISSUE 
200-208 19 31.7 
ACUTE MYELOID LEUKEMIA 205.0 18 30.0 
CHRONIC MYELOID LEUKEMIA 205.1 21 35.0 
OTHER MALIGNANT NEOPLASM  140-199 7 11.7 
DISEASES OF THE CIRCULATORY SYSTEM 390-459 16 26.7 
DIABETES MELLITUS 250 28 46.7 
DISEASES OF THE RESPIRATORY SYSTEM  460-519  6 10.0 
DISEASES OF THE DIGESTIVE SYSTEM 520-579 15 25.0 
DISEASES OF THE GENITOURINARY SYSTEM 580-629 8 13.3 
INFECTIOUS AND PARASITIC DISEASES 001-139 2 3.3 
DISEASES OF THE MUSCULOSKELETAL SYSTEM 
AND CONNECTIVE TISSUE 
710-739 7 11.7 
PATHOLOGIC FRACTURE 733.1 2 3.3 
TRAUMATISM 800-959 4 6.7 
CHEMOTHERAPY V58.1 6 10.0 
TRANSFUSIONS V58.2 1 1.7 
 
  www.mjhid.org Mediterr J Hematol Infect Dis 2017; 9; e2017046                                                         Pag. 6 / 11 
 
diseases of the blood and blood-forming organs). 
For the remaining 60 patients, the distribution of 
the main diagnosis during their 203 hospitalization 
episodes is reported in Table 4. For these patients, 
the sum is not 60 because each patient could have 
been hospitalized more than once. 
 
Mortality follow-up. The median observation time 
for the 556 MDS patients with evaluable survival 
data was 46 months (range: 0.9 - 130 months). 
During the follow-up, 253 deaths (45.5% patients) 
occurred. Of whom, 158 (62.5%) were men. 
Figure 1A shows the OS curve expressed as 
months for the whole 2002-2012 period. 
The frequency distribution of survived and 
deceased patients along the whole follow up 
period stratified by type of MDS are reported in 
Table 5. Figure 1B illustrates the survival curve 
stratified by MDS type according to  2008 WHO 
classification. The median survival of specific 
MDS subpopulations was: 5q- syndromes: 110 
months, MDS-U: not reached, RA: 102 months, 
RCMD: 93 months, RARS: 80 months, RAEB I: 
37 months, RAEB II: 24 months. At the end of the 
follow up 58.9%, 62.5% and 57.1% of patients 
with RCMD, RA and RARS were alive. Survival 
was 36% and 34% for patients with RAEB I and
 
 
Figure 1. Survival. A. Overall survival. B. Overall survival stratified by the type of MDS: In low-risk MDS, survival of RCMD and RARS 
are coincident until month 47 of follow-up, later-on the RCMD curve slightly fell. Survival of RA patients, compared to RCMD and RARS, 
shows a lower death rate before month 80 and higher afterwards. This might be influenced by the fact that RARS patients are fewer (N=28) 
than RCMD (N=129) and RA patients (N=195). In the high-risk group, death rates for RAEB II are higher at the beginning: 59% of RAEB II 
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Patiens died  Patients survived 
N % N % 
5q- 24 8 33.33 16 66.67 
MDS-U 23 5 21.74 18 78.26 
RA 195 73 37.44 122 62.56 
RAEB I 86 55 63.95 31 36.05 
RAEB II 71 47 66.20 24 33.80 
RCMD 129 53 41.09 76 58.91 
RARS 28 12 42.86 16 57.14 
TOTAL 556 253 45.50 303 54.50 
 
RAEB II (Table 5). Patients with a 5q- syndrome 
or an MDS-U had the best survival probability 
(67% and 78%, respectively). The last observed 
death in MDS-U patients occurred at 22 months, 
while it occurred at 112 months in 5q-patients. 
The Log-Rank test confirmed a statistically 
significant difference among the patient sub-
groups (p-value <0.0001). 
The distribution of patients alive at last follow-
up, stratified by year of diagnosis at one year and 
five years are reported in Table 6, no significant 
differences in survival according to  the time of 
diagnosis were observed. 
Figure 2 shows the five-year survival curve 
according to the year of MDS diagnosis, no 
significant differences were observed among the 
six curves (Log-Rank test=0.593). 
The distribution of the most frequent causes of 
death, according to ICD-9-CM coding, is 
described in Table 7. The number of fatalities 
from acute leukemia accounts for 41% in high-risk 
MDS and 21% in low-risk MDS, respectively. 
Interestingly, a relevant portion of death causes is 
represented by cerebro-cardiovascular events and 
second tumors. The most frequent cause of 
mortality was “acute myeloid leukemia” (ICD-9-
CM code 2050) which accounts for 23% causes of 
death (data not shown), “other lymphatic and 
hematopoietic tissues” (ICD-9-CM code 238.7) 
was the second cause of death, while 12% of 
deaths were due to other hematologic diseases. 
 
Discussion. Here, we report the first regional 
Lazio study on diagnosis, sub-classification,  and 
survival of MDS patients. MDS patients are often 
difficult to recognize, and diagnostic difficulties 
might affect reporting frequency.13,21,22 Our results 
confirm these issues in the Lazio Region.2,23-25 
MDS are hematologic diseases whose 
identification and classification criteria have 
undergone major changes in recent years. 
Although it is difficult to recognize by the 
clinicians, awareness on this disease among 
hematologists has increased in the last years. In 
particular, the GROM-L registry required that 
diagnoses reported in the present study were 
accurate and homogeneously assessed by all 
participating hematologic centers. 
Among the 644 patients enrolled, we could 
evaluate only those who had a valid AUPC and a 
hospitalization episode (regularly or day hospital 
regimen) in the period from the  date of diagnosis 
to December 31, 2012 (up to 11 years). 
Discrepancies between the GROM-L registry and 
administrative databases are due to incorrect 
reporting of the personal data, leading to an 
invalid AUPC. Thus, health care information was 
retrieved for 442 patients only (64.6%). In 71.5% 
 
Table 6. Distribution of patients alive stratified by year of diagnosis at one year follow up and at five years follow up. 
  Patients survived after ONE year of follow-
up 
Patients survived after FIVE year of 
follow-up 
Year of MDS diagnosis N N % N % 
2002 23 22 95.7 16 69.6 
2003 31 30 96.8 19 61.3 
2004 35 35 100.0 25 71.4 
2005 58 53 91.4 34 58.6 
2006 60 54 90.0 34 56.7 
2007 86 78 90.7 49 57.0 
Total 293 272 
 
177 60.4 
      
2008 95 89 93.7 
  
2009 96 84 87.5 
  
2010 72 64 88.9 
  
TOTAL 556 509 91.5 
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Figure 2. Survival stratified by year of MDS diagnosis – 5 year follow-up. 
 
No significant differences in survival according to time of diagnosis are observed. 
 
Table 7. Distribution of the causes of death (ICD-9-CM coding) stratified by MDS subtype. 
Cause of death ICD-9-CM code RAEB I and II Other MDS diagnoses Total 
 N % N % N % 
Acute Leukemia 2040, 2050, 2070, 2080 42 41 32 21 74 29 
MDS (neoplasm of uncertain behavior 
of other lymphatic and hematopoietic 
tissues) 
2387 22 22 33 22 55 22 
cardio-cerebrovascular disease 
(including diabetes) 
2500, 2502, 2506, 4029, 
4100, 4140, 4149, 4148, 
4241, 4254, 4280, 4291, 
4293, 4299, 4321, 4360, 
4371, 4379, 5184, 5570, 
5715, 8521, 9960 
13 13 30 20 43 17 
Other hematologic diseases 2019, 2028, 2029, 2058, 
2059, 2069, 2089, 2849, 
2850, 2898, 2041, 2051 
16 16 15 10 31 12 
Tumours (other than hematologic) 1519, 1533, 1536, 1539, 
1551, 1560, 1579, 1590, 
1629, 1749, 1850, 1890, 
2307 
4 4 20 13 24 9 
OTHER CHRONIC DISEASES (lung, 
intestine, liver, bone etc...) plus 
unknown 
381, 384, 2858, 2859, 2890, 
2892, 4912, 5698, 5712, 
5761, 5850, 7425, 7999, 
8210 
4 4 19 13 23 9 
Infections 4210, 4850, 5580 1 1 2 1 3 1 
TOTAL  102 100 151 100 253 100 
 
of these patients, the code 238.7 (Myelodysplastic 
Syndrome) was recorded at least once in one of 
the hospital admissions. As in previous studies,26 a 
high proportion of non-specific MDS codes was 
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reported. In the remaining 28.5% of patients, the 
primary diagnosis was hematologic in more than 
half of hospital admissions. 
Our observation confirms that survival of 
patients with MDS is poor. The OS curve (Figure 
1A) is similar to other large analysis,1,6 although 
different study cohorts are not comparable, as 
observed in the recent report of Della Porta et al.,27 
mainly due to different proportion of high risk 
patients and variable median age. The Kaplan-
Meier curve stratified by MDS subtype according 
to 2008 WHO classification (Figure 1B), is 
similar to other studies of the same type,28 with 
shorter survival for patients with RAEB I or 
RAEB II. Survival was similar in low-risk MDS 
(RCMD, RA, and RARS), and it reached a plateau 
in high-risk MDS (RAEB I and RAEB II), similar 
to other registries.1,6 Patients with a 5q- syndrome 
survived the longest, followed by MDS-U patients, 
although numbers are low (24 and 23 patients, 
respectively). This is due to the favorable 
cytogenetic category and probably to the recently 
introduced lenalidomide treatment.  
These results confirm data from a smaller 
patient group (380 patients) previously analyzed 
by our group,29 which was used to validate the 
IPSS-R, compared to IPSS and WPSS. 
MDS patients’ therapy has improved over the 
past decades after the introduction of new 
treatment strategies. We performed a survival 
analysis stratified by year of diagnosis to 
investigate a possible survival gain over time, as 
assessed by existing literature,30,31 but no 
significant differences in survival were seen at one 
year and five years follow up. These results could 
be due to the low proportion of patients eligible 
for new treatment strategies (high risk MDS and 
5q- syndrome).  
During the follow up almost half of the patients 
died. 29% of deaths are ascribable to acute 
leukemia (Table 7), in particular, acute myeloid 
leukemia (2050 ICD-9-CM code) is the first cause 
of death; indeed it represents a natural evolution of 
the disease.32 The second cause of death is MDS 
(2387 ICD-9-CM code), but 12% of deaths are due 
to other hematologic diseases, this could indicate 
mis-classification also in the causes of death. 
An important focus of our “real life” 
observation is the impact of comorbidity on 
survival, which induced physicians to choose the 
comorbidity code, instead of the MDS code, as the 
first diagnosis in the hospital report. Furthermore, 
we observed that mortality causes in low-risk 
MDS patients’ include not only hematologic 
diseases but also cerebro-cardiovascular events 
and second tumors. In particular, 20% of low risk 
patients died of cerebro-cardiovascular events and 
13% of second tumors. This finding draws 
attention to comorbidity assessments to increase 
patients’ survival and quality of life. Our 
observation is in line with most recent reports on 
the negative prognostic value of comorbidity not 
only per se but also in the context of the different 
therapeutic strategies, which may increase the risk 
of complications.27,33,34 
All these results can be interpreted in several 
ways including: 1) inappropriate use of existing 
ICD-9-CM codes; 2) misclassification with other 
blood disorders; 3) evolution of the disease over 
time (which justifies the use of codes specific for 
different hematological diseases). 
Moreover, it is important to stress the 
limitations of ICD-9-CM classification currently 
utilized in the HIS, as well as of the more recent 
ICD-10-CM. In fact, the MDS subtypes are 
identifiable only by evolving complex algorithms, 
based on various criteria including symptoms, 
laboratory tests and molecular genetic 
investigations that will further change with the 
application of   2016 WHO classification.35 
This study highlights for the first time in the 
Lazio Region that diagnosis and treatment of 
MDS, which require a considerable use of 
healthcare resources, tend to be under-documented 
in the HIS archive, due to difficulties in 
recognition and coding. We need instruments to 
improve the HIS, increasing sensitivity and 
specificity in order to capture information on MDS 
hospitalizations and outcome.  
The strength of our study is the existence of an 
updated and verified MDS regional registry. One 
limit is the possible incomplete link between the 
GROM-L registry and the administrative 
databases, which drives to the absence of a valid 
AUPC with a consequent loss of patients in the 
examined cohort. 
The registry could be a useful investigational 
tool to perform continued surveillance of MDS, 
effective to monitor potential misdiagnosis and 
underreporting of these conditions  and to collect 
clinical and epidemiological data for future 
prevention and treatment strategies. 
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